S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
NASDAQ:ORIC

ORIC Pharmaceuticals - ORIC Earnings Date, Estimates & Call Transcripts

$4.71
-0.13 (-2.69%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.57
$4.83
50-Day Range
$3.60
$5.24
52-Week Range
$2.62
$26.70
Volume
60,141 shs
Average Volume
441,939 shs
Market Capitalization
$185.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Earnings Summary

Upcoming
Earnings Date
Nov. 14Estimated
Actual EPS
(May. 9)
-$0.59 Missed By -$0.02
Consensus EPS
(May. 9)
-$0.57
Last Year's Q2 EPS
(5/6/2021)
-$0.45
Skip Charts & View Estimated and Actual Earnings Data

ORIC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ORIC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ORIC Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20222($0.59)($0.58)($0.59)
Q2 20222($0.60)($0.56)($0.58)
Q3 20222($0.61)($0.55)($0.58)
Q4 20222($0.64)$0.57($0.04)
FY 20228($2.44)($1.12)($1.78)

ORIC Earnings Date and Information

ORIC Pharmaceuticals last announced its earnings results on May 9th, 2022. The reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.02. ORIC Pharmaceuticals has generated ($2.15) earnings per share over the last year (($2.15) diluted earnings per share). Earnings for ORIC Pharmaceuticals are expected to decrease in the coming year, from ($2.44) to ($2.77) per share. ORIC Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 14th, 2022 based off prior year's report dates.

ORIC Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/14/2022
(Estimated)
        
5/9/2022Q1 2022($0.57)($0.59)($0.02)($0.59)  
3/21/2022Q4 2021($0.61)($0.58)+$0.03($0.58)    
11/8/20219/30/2021($0.58)($0.47)+$0.11($0.47)
8/10/20216/30/2021($0.49)($0.57)($0.08)($0.57)
5/6/20213/31/2021($0.48)($0.45)+$0.03($0.45)  
3/22/2021Q4($0.4640)($0.84)($0.3760)($0.84)
11/5/20209/30/2020($0.39)($0.84)($0.45)($0.84)  
8/5/20206/30/2020($0.37)($0.51)($0.14)($0.51)  
5/20/2020Q1($0.2640)($4.46)($4.1960)($4.46)












ORIC Pharmaceuticals Earnings - Frequently Asked Questions

When is ORIC Pharmaceuticals's earnings date?

ORIC Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 14th, 2022 based off last year's report dates. Learn more on ORIC's earnings history.

Did ORIC Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, ORIC Pharmaceuticals (NASDAQ:ORIC) missed the analysts' consensus estimate of ($0.57) by $0.02 with a reported earnings per share (EPS) of ($0.59). Learn more on analysts' earnings estimate vs. ORIC's actual earnings.

How can I read ORIC Pharmaceuticals's conference call transcript?

The conference call transcript for ORIC Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much profit does ORIC Pharmaceuticals generate each year?

ORIC Pharmaceuticals (NASDAQ:ORIC) has a recorded net income of -$78.71 million. ORIC has generated -$2.15 earnings per share over the last four quarters.

What is ORIC Pharmaceuticals's EPS forecast for next year?

ORIC Pharmaceuticals's earnings are expected to decrease from ($2.44) per share to ($2.77) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:ORIC) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.